Stockscreener 앱 받기
52.15
0.38%
0.20
시간 외 거래:
52.29
0.14
+0.27%
Bristol Myers Squibb Co 주식(BMY)의 최신 뉴스
Antibody Discovery Market to Reach USD 17.68 Billion by 2032, Driven by Rising Demand for Targeted Therapies and Advancements in AI Powered Antibody Engineering – SNS Insider - GlobeNewswire Inc.
Cresset Asset Management LLC Decreases Stock Holdings in Bristol Myers Squibb Company $BMY - MarketBeat
Bristol Myers Squibb Company $BMY Shares Sold by Epoch Investment Partners Inc. - MarketBeat
Jim Cramer on Bristol-Myers’ Recent Stock Gain: “Unbelievable” - Insider Monkey
What's Going On With Bristol-Myers Squibb Stock Friday?Bristol-Myers Squibb (NYSE:BMY) - Benzinga
Bristol Myers Squibb CEO Chris Boerner says company culture was the missing piece of his ‘patent cliff’ plan - Fortune
First Trust Advisors LP Has $212.59 Million Holdings in Bristol Myers Squibb Company $BMY - MarketBeat
Bristol Myers Squibb’s Breyanzi Approved by the U.S. FDA as the First and Only CAR T Cell Therapy for Adults with Relapsed or Refractory Marginal Zone Lymphoma (MZL) – Company AnnouncementFT.com - Financial Times
DEERFIELD MANAGEMENT COMPANY, L.P.'s Bristol-Myers Squibb Co(BMY) Holding History - GuruFocus
Rx Rundown: Bristol Myers Squibb, Retro Bio, Ionis Pharmaceuticals and more - Medical Marketing and Media
How risky is Bristol Myers Squibb Company stock compared to peers2025 Market WrapUp & Free Risk Controlled Daily Trade Plans - Newser
Bristol Myers Pushes Data Readout For Key Alzheimer's Psychosis Study After Irregularities - Sahm
BMY Gains on News of Continuation of Alzheimer's Disease Study - Finviz
Florida key to BMS slip in ADP? Acadia sails ahead - BioWorld MedTech
Scotiabank raises Bristol-Myers Squibb stock price target to $53 on pipeline - Investing.com Nigeria
Invesco Ltd. Raises Stock Position in Bristol Myers Squibb Company $BMY - MarketBeat
CW Advisors LLC Increases Stock Holdings in Bristol Myers Squibb Company $BMY - MarketBeat
Why Bristol Myers Squibb Company Celegne Contingent stock is a must watch tickerGlobal Markets & Stock Timing and Entry Methods - Newser
Bristol-Myers Squibb (BMY) Stock Surges on Cobenfy Trial Twist and AI Milestone: Full Outlook as of December 3, 2025 - ts2.tech
What's Going On With Bristol-Myers Squibb Shares Wednesday?Bristol-Myers Squibb (NYSE:BMY) - Benzinga
Shares of Bristol Myers Squibb rise despite delay in clinical trial of promising drug - MarketWatch
Bristol-Myers Squibb stock holds Buy rating at Truist despite trial delay - Investing.com
A delayed clinical trial actually boosted Bristol Myers Squibb’s stock. Here’s why. - MarketWatch
After finding ‘irregularities,’ Bristol Myers to extend key trial of Cobenfy in Alzheimer’s psychosis - BioPharma Dive
Bristol Myers Squibb (BMY) Delays Alzheimer's Drug Trial Results - GuruFocus
Bristol Myers (BMY) Extends ADEPT-2 Study Timeline for Key Alzhe - GuruFocus
Bristol Myers (BMY) Advances in Alzheimer's Study Facing Trial C - GuruFocus
Bristol Myers (BMY) Bolsters ADEPT-2 Alzheimer's Study with More Participants - GuruFocus
Terray Therapeutics Achieves AI-Enabled Drug Discovery Milestone in Collaboration with Bristol Myers Squibb - Yahoo Finance
Bristol Myers Stock Jumps As Wall Street Backs Added Enrollment In Alzheimer’s Trial — Retail Calls It ‘Worth A Play’ - Stocktwits
Drug Trial Wins Give Health Care Stocks A Shot - Finimize
Bristol Myers Squibb Company (BMY) Is a Trending Stock: Facts to Know Before Betting on It - Yahoo Finance
Bristol Myers rises as Alzheimer's trial to enroll more patients - TradingView
M&T Bank Corp Sells 23,588 Shares of Bristol Myers Squibb Company $BMY - MarketBeat
Bristol Myers (BMY) Expands ADEPT-2 Study to Address Irregularit - GuruFocus
River Road Asset Management LLC Sells 67,650 Shares of Bristol Myers Squibb Company $BMY - MarketBeat
BMS to enroll more patients in Alzheimer’s psychosis drug trial - Investing.com
Bristol Myers Squibb stock rises after continuing Phase 3 Alzheimer’s study - Investing.com Canada
Loomis Sayles & Co. L P Boosts Stake in Bristol Myers Squibb Company $BMY - MarketBeat
Independent Franchise Partners LLP Increases Holdings in Bristol Myers Squibb Company $BMY - MarketBeat
Bristol-Myers Stock Rises on Alzheimer’s Drug Study Update - The Wall Street Journal
Cantor Fitzgerald Maintains Price Target on Bristol-Myers (BMY) Amid Milvexian Updates - Insider Monkey
BMS Executive: AI to Reshape Pharmaceutical, Biotech Industries - 조선일보
Bristol-Myers Squibb (BMY): Assessing Value After a Recent Short-Term Share Price Rebound - simplywall.st
Bristol Myers Squibb Co. stock underperforms Tuesday when compared to competitors - MarketWatch
Judge Trims but Revives Core Claims in Bristol-Myers $6.7B Suit - USA Herald
BMY: Goldman Sachs Raises Bristol-Myers Squibb Price Target to $57 | BMY Stock News - GuruFocus
Bristol-Myers to Face $6.7 Billion Celgene Deal Payout Suit (1) - Bloomberg Law News
Wealthedge Investment Advisors LLC Buys New Holdings in Bristol Myers Squibb Company $BMY - MarketBeat
Shelton Capital Management Cuts Stock Holdings in Bristol Myers Squibb Company $BMY - MarketBeat
Claret Asset Management Corp Grows Position in Bristol Myers Squibb Company $BMY - MarketBeat
Bristol Myers Squibb (BMY) Faces $6.7 Billion Lawsuit Over Celge - GuruFocus
State Farm Growth Fund's Bristol-Myers Squibb Co(BMY) Holding History - GuruFocus
Judge Rules Bristol Myers Must Face $6.7B Lawsuit Over Delayed Cancer Drug - Claims Journal
Bristol-Myers Must Face Trimmed $6.7B Celgene Investor Suit - Law360
Bristol-Myers Squibb (BMY) Stock Today: Lawsuit Shock, Breyanzi Momentum and 2026 Forecast - ts2.tech
Bristol Myers must face $6.7 billion lawsuit over delayed cancer drug, US judge rules By Reuters - Investing.com
Bristol Myers must face $6.7 billion lawsuit over delayed cancer drug, US judge rules - Yahoo Finance
Judge rejects Bristol Myers Squibb’s bid to dismiss $6.7 billion lawsuit - Investing.com Canada
Here's Why Bristol Myers Squibb (BMY) is a Strong Value Stock - Yahoo Finance
Trustmark Bank Trust Department Sells 32,341 Shares of Bristol Myers Squibb Company $BMY - MarketBeat
XTX Topco Ltd Buys New Shares in Bristol Myers Squibb Company $BMY - MarketBeat
Bristol Myers Squibb Unveils Positive Trial Data In Hematology Pipeline - Nasdaq
Bristol Myers Squibb Data At Ash 2025 Showcase Potential Of Hematology Pipeline And Build Momentum For Next Generation Portfolio - TradingView
Bristol Myers (BMY) Showcases Breakthroughs in Hematology at ASH Meeting - GuruFocus
Groupama Asset Managment Cuts Stock Holdings in Bristol Myers Squibb Company $BMY - MarketBeat
Bristol-Myers Squibb: A Pivotal Moment for the Pharmaceutical Giant - Ad-hoc-news.de
BioNTech (BNTX) Is Up 7.9% After Raising 2025 Revenue Guidance on Bristol-Myers Collaboration - Yahoo Finance UK
BMY Gains Attention as Bayer Reports FXIa Trial Success - Finviz
Schroder Investment Management Group Increases Stock Position in Bristol Myers Squibb Company $BMY - MarketBeat
1.21%
0.98%
자본화:
|
볼륨(24시간):